Skip to main content

Drug Interactions between fruquintinib and Xtandi

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

enzalutamide fruquintinib

Applies to: Xtandi (enzalutamide) and fruquintinib

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of fruquintinib, which is primarily metabolized by the isoenzyme. Concomitant use with rifampin, a potent CYP450 3A4 inducer, decreased fruquintinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 12% and 65%, respectively. Reduced efficacy of fruquintinib may occur.

MANAGEMENT: Coadministration of fruquintinib with potent CYP450 3A4 inducers should be avoided.

References

  1. "Product Information. Fruzaqla (fruquintinib)." Takeda Pharmaceuticals America (2023):

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.